Skip to main
CDNA

CareDx (CDNA) Stock Forecast & Price Target

CareDx (CDNA) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 17%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

CareDx Inc. demonstrated a robust financial performance, with a 21% year-over-year growth in top-line revenue for Q3, fueled by a 13% increase in volume and a 5% rise in average selling prices. The company also achieved its highest cash collections in history in October and recorded a notable 19% growth in kidney surveillance volumes in the previous quarter, showcasing strong demand for its testing services. Furthermore, a substantial expansion of its sales force by approximately 50% is expected to enhance future revenue growth, positioning CareDx favorably in the precision medicine market for transplant patients.

Bears say

CareDx Inc. experienced a year-over-year growth in testing volumes of 13%, but the Q3'25 results fell short of expectations, with actual volumes at 50,000 compared to the anticipated 51,000, signaling potential challenges in volume growth despite a 20% increase in surveillance testing. The company's stock performances have faced pressure, trading significantly below historical averages at 1.4x projected 2026 revenue estimates, indicating investor concerns about the future profitability and competitiveness within the diagnostics space. Additionally, CareDx's ongoing risks include management instability over the past three years and uncertainty regarding the commercialization of new diagnostic solutions, which are critical for its growth strategy.

CareDx (CDNA) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 17% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CareDx (CDNA) Forecast

Analysts have given CareDx (CDNA) a Buy based on their latest research and market trends.

According to 6 analysts, CareDx (CDNA) has a Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CareDx (CDNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.